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MEDICATION PERSISTENCE IN THE TREATMENT OF HIV INFECTION: A 
NEW CONSTRUCT FOR HIV RESEARCH AND CLINICAL CARE. Jason W. 
Bae, Eileen C. Ing, Duncan S. Maru, William Guyer, Kristy Grimm, and Frederick 
L. Altice. Section of Infectious Diseases, Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT 
 
Adherence to therapy has dominated clinical and investigational conversation on 
how HIV patients take medications. Adherence, although a critical concept in 
medication-taking behavior, is becoming increasingly limited in its relevance to 
patient outcomes as treatment regimens and our understanding of antiretroviral 
resistance development evolve over time. In this thesis, a new construct of HIV 
medication-taking behavior called ‘persistence’ is introduced and defined, in order 
to provide researchers and practitioners with a more comprehensive understanding 
of patient behavior and achieve better health outcomes. Literature review of 
adherence, persistence, viral suppression, development of antiretroviral resistance is 
performed here to reveal patient, medication, and healthcare setting characteristics 
associated with suboptimal persistence. Impact of persistence on resistance 
development and clinical outcomes is also summarized. Finally, patterns of non-
persistence among HIV-infected drug users undergoing directly-administered 
antiretroviral therapy in a prospective, randomized-controlled trial are presented 
along with factors associated with non-persistence. This study suggests that 
decreased persistence for HIV treatment, or shorter duration on therapy, is 
associated with increased rates of virological failure, development of antiretroviral 
resistance, and increased morbidity and mortality. Additionally, frequency and 
duration of non-persistent episodes rather than adherence may be a better predictor 
of clinical outcomes in HIV-infected patients on certain regimens. More emphasis on 
persistence when considering HIV medication-taking behavior in both clinical and 
research setting is warranted.  
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1. Introduction 
 
 Multiple terms, oftentimes expressing different constructs yet with some 
overlap, have been used to explain how well a patient takes their medications. 
These terms, such as adherence, compliance, persistence, and durability, are 
often used interchangeably, sometimes lead to inaccurate or imprecise 
interpretation of patient behavior, and may result in incorrect conclusions about 
which intervention should be appropriately deployed. Much of the early 
research and attention to medical management of HIV/AIDS has been focused 
on the construct of adherence. Especially early in the HIV/AIDS epidemic when 
regimens were often complicated, had large pill burdens, complex dosing 
schedules, and low genetic barriers to resistance, adherence played an important 
role in HIV treatment. Indeed, a large body of literature has repeatedly 
demonstrated the importance of adherence, where a high level of adherence to 
antiretroviral therapy was associated with successful viral suppression and 
decreased morbidity. Treatment strategies, however, have changed.  In 
recognition of the changing HIV epidemic and the various subpopulations 
globally who will eventually access contemporary combination antiretroviral 
therapy (cART), we provide insight into additional considerations and define the 
construct of persistence, and its operationalization for clinical care and research 
in the context of HIV treatment. Additionally, we summarize methods for 
determination of persistence and current literature on persistence in HIV 
treatment.  
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The Dynamics of HIV Replication and Impact on Treatment 
 Decreased adherence to or discontinuation of a prescribed therapy is 
likely to result in unfavorable health outcomes in chronic diseases, such as 
hypertension, hyperlipidemia, congestive heart failure, or chronic obstructive 
pulmonary disease. Management of HIV differs from other chronic diseases in 
that successful control of the disease is more complex and also the consequences 
of failure may be greater. First, suppression of viral replication requires lifelong 
retention on cART, often consisting of 3 or more medications. Second, unlike in 
hypertension or diabetes, inconsistent use of medications leads to development 
of resistance to one or more medications in the regimen, thereby limiting future 
treatment options and complicating therapy. Last, failure to suppress viral 
replication not only affects the health of the patient, but also increases the risk of 
HIV transmission to others who engage in high risk behaviors, posing greater 
public health concerns than with non-communicable diseases.  
Management of HIV has changed dramatically in recent years.  Lessons 
learned from the SMART trial where subjects randomized to discontinue cART 
until pre-specified CD4 thresholds were met had increased non-HIV and HIV-
related morbidity and mortality compared to those who continuously remained 
on therapy (1).  This finding emphasizes more than ever that “remaining” on 
therapy is crucial, and so is the need for interventions that allow treatment to 
“persist over time.”  
 Antiretroviral treatment itself has also changed.  Development of highly 
potent, once-daily, low pill burden, and more tolerable cART has greatly 
improved and altered the landscape of contemporary HIV management (2). 
Contemporary regimens are affected less by perturbations in adherence, in part 
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due to the high genetic barrier to resistance by some medications (e.g., ritonavir-
boosted protease inhibitors) and long half lives of others (e.g., non-nucleoside 
reverse transcriptase inhibitor, NNRTI). For example, nevirapine, a NNRTI, has a 
serum half-life of 48 hours (3) and its serum level remains detectable 1 week after 
discontinuation (4). On the other hand, abacavir and lamivudine, nucleoside 
reverse transcriptase inhibitors (NRTI), have much shorter serum half-lives of 1.5 
and 6 hours, respectively (5, 6) and the intracellular concentration of the active 
abacavir metabolite becomes undetectable within 72 hours after the last dose (7). 
Therefore, discontinuation of a multi-drug regimen such as the one above for 3 
days or more may result in extended nevirapine monotherapy, during which 
selective pressure on viral replication may result in development of resistance 
due to the low genetic barrier to resistance by NNRTIs (8). In the case of 
nevirapine administered even as a single-dose monotherapy regimen to prevent 
mother-to-child-transmission of HIV, high rates of NNRTI resistance have been 
observed among mothers and infants (9, 10). Efavirenz, a preferred NNRTI 
component of contemporary regimens, also has a prolonged serum half-life of 
40-55 hours, and like nevirapine, can remain at a therapeutic dose for longer than 
21 days after discontinuation (11).  Pharmacokinetic profiles of NNRTIs like 
efavirenz and nevirapine have the benefit of continuing to suppress HIV 
replication when medications are stopped briefly, but may be detrimental when 
treatment regimens are discontinued for longer periods due to their low genetic 
barrier to resistance when HIV replication is not completely suppressed.  
Ritonavir-boosted protease inhibitor regimens, also part of preferred 
cART regimens, do not have prolonged serum half-lives like NNRTIs. These 
antiretroviral agents, however, have other pharmacological advantages due to 
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their high genetic barrier to resistance such that even prolonged periods of 
monotherapy potently suppress HIV replication, yet seldom result in the 
development of resistance mutations (12, 13). As such, they pose few problems 
when there is poor adherence or decreased persistence.  
In a proof-of-concept pilot study, subjects who were on a suppressive 
once-daily antiretroviral regimen were changed to five days on treatment and 
then provided with a two-day holiday (72 hours since last dose); all subjects on 
an efavirenz-containing regimen and 90% of those on a nevirapine-containing 
regimen had suppressed HIV-1 RNA levels at 48 weeks suggesting that intervals 
< 72 hours do not negatively impact clinical outcomes (14). On the other hand, 
two out of nine subjects on a PI-based regimen had experienced virological 
rebound by 48 weeks. In another trial, where antiretroviral therapy was 
interrupted every other week in a “1 week on, 1 week off” strategy, 1 of 8 
patients on an efavirenz-based regimen experienced virological failure with a 
resultant new resistance mutation to efavirenz. In contrast, 11 of 17 patients on a 
regimen containing ritonavir-boosted-saquinavir experienced virological failure, 
however, none developed a new resistance mutation to a PI (15). These studies 
suggest that the duration for which therapy may be discontinued without 
expecting an adverse outcome differs depending on antiretroviral composition of 
a regimen. This “permissible gap” (see below for definition) is most likely to be 
between 2 to 7 days for a regimen containing efavirenz, but further investigations 
are needed to better characterize the permissible gap that results in adverse 
consequences. 
 Adherence, rather than persistence, has been the center of focus in 
research of medication-taking behaviors among HIV-infected patients (see below 
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for definition). Contrary to the pervasive view that low adherence leads to 
development of resistance, data suggest that the relationship between adherence 
and resistance may be more complex (16), particularly when contemporary 
preferred regimens are prescribed (Figure 1). For example, NRTI and PI 
resistances were observed predominantly in highly adherent individuals in a 
cohort study (17). In other studies, development of resistance to PIs was limited 
to individuals with adherence greater than 90% (18) and imperfect adherence of 
many ritonavir-boosted PI-containing regimens does not result in significant 
levels of resistance (19). Emerging data from recent studies question the long-
taught principle that “non-adherence leads to development of resistance and 
virological failure” and also the construct of adherence itself and its applicability 
in the current setting of HIV treatment. 
 In sum, adherence alone when using contemporary treatment regimens 
may be insufficiently predictive of clinical outcomes in HIV-infected patients and 
is dependent on the type of regimen prescribed. Clinical care and research in the 
management of HIV would therefore benefit from an additional “time-
dependent” measure of medication-taking behaviors. 
 
2. Aims  
The purpose of this thesis is to introduce the construct of medication persistence 
for HIV and present patterns of and characteristics associated with medication 
persistence.  
 
Specific Aims 
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1)  Define the construct of medication persistence in the setting of HIV 
treatment and propose methods for determining persistence. 
2)  Using a review of available literature; 
2A)  Describe patterns of medication non-persistence and their impact 
on development of antiretroviral resistance and clinical outcomes.  
2B)  Describe patient, medication, and healthcare settings characteristics 
associated with persistence.  
3)  In a retrospective analysis of a randomized controlled trial of directly-
administered anti-retroviral therapy (DAART) vs. self-administered  
therapy (SAT); 
3A)  Describe patterns of medication among HIV-infected drug users 
undergoing DAART. 
3B)  Present medication and patient characteristics associated with non-
persistence.  
3C)  Explore the relationship between non-persistence and virological 
success. 
 
3. Methods 
 
Literature Review and Definition of Persistence (AIMS 1 & 2) 
PubMed and Medline database were searched jointly by Jason Bae and 
Frederick Altice for literature review of adherence, persistence, durability and 
their relationship with antiretroviral resistance, viral suppression, and mortality. 
The original idea of the manuscript was suggested by Frederick Altice. Jason Bae 
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developed and refined the construct of persistence in the setting of HIV 
treatment. The manuscript was jointly written by Jason Bae and Frederick Altice.  
 
Patterns of Non-Persistence and Associated Characteristics from Project Trust (AIM 3) 
Persistence data from Project Trust (National Institutes on Drug Abuse 
R01 DA13805) were obtained as following. A 6-month, randomized controlled 
study of directly-administered antiretroviral therapy (DAART) was conducted 
among 141 drug users led by Frederick Altice. Primary outcomes of this project 
are published elsewhere (20). Participants were recruited from all of the HIV 
clinics in New Haven, Connecticut. Entry criteria included: (1) being HIV 
seropositive; (2) being eligible for and/or being prescribed antiretroviral 
medications; (3) residing within the city of New Haven; (4) active use of heroin 
and/or cocaine in the previous 6 months; and (5) receiving no more than a twice-
daily regimen. Following informed consent, eligible participants were 
randomized 2:1 to DAART or self-administered therapy. 
 DAART participants received their antiretroviral medications at a mobile 
health unit that traveled to four New Haven inner city neighborhoods on 
weekdays (21). All medication doses were placed in small plastic bags in a 
medication bottle with a Medication Electronic Monitoring System (MEMS) 
Version 6 Smart Cap (Aardex). A trained outreach worker observed one daily 
dose; all other doses were provided for the patient to take later, with a reminder 
from a beeper. Weekend doses were dispensed on Fridays and each patient had 
up to 3 days of an emergency supply of antiretroviral medications that were 
stored in the MEMS bottle. In this study, only those participants who were 
randomized to and initiated DAART were included in the analysis. 
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Virological success at 6 months for this predominantly antiretroviral-
experienced population was defined a priori as having achieved an HIV-1 RNA 
level reduction of at least 1.0 log10 copies/ml or an HIV-1 RNA level < 400 
copies/ml at 6 months. Missing values were imputed as virological failure.  
Persistence was calculated using a combination of daily DAART 
observations and MEMS event data during the 6-month period of DAART. 
Subjects were considered to be on treatment for a given day if either there was: 
(1) an observed DAART dose or (2) a MEMS event. Missed DAART 
appointments due to hospitalization or imprisonment were corrected from 
verifiable clinical records of medication administration in these institutions.  
Non-persistence was defined for three thresholds at any point during the 
6-month intervention period: (1) ≥ 3 days (missing more than 2 consecutive days 
of antiretroviral medications); (2) ≥ 5 days; and (3) ≥ 7 days. Once a participant 
met the defined threshold gap, he or she was considered to be non-persistent. To 
determine the recurrence and true extent of non-persistence, all interruptions in 
treatment exceeding the proposed permissible gaps were considered to be non-
persistent episodes. Recurrent non-persistence was defined as having more than 
one non-persistent episode, defined as gaps ≥ 3 days, within the 180-day 
observation period of the study. Time to patient non-persistence was defined as 
the number of days to the 1st day of a pre-defined first episode of non-
persistence. Patients who were lost to follow-up were considered non-persistent 
from day of DAART discontinuation to day 180 of observation.  
Regimen non-persistence was defined as any change in any component of 
the initial antiretroviral medication regimen. Time to regimen non-persistence 
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was measured as the number of days between DAART initiation and regimen 
modification.  
Baseline interviews assessed an array of psychosocial, demographic, and 
drug use characteristics. Addiction severity was assessed using binary outcomes 
(high severity if score ≥ 6) using the 10-item Drug Abuse Screening Test (DAST-
10), a self-report measure of problematic substance use, widely used for clinical 
screening and research (22). The Center for Epidemiological Studies Depression 
Scale (CES-D) (23), a 20-item self-report scale to measure depressive 
symptomatology, is highly correlated with having major depression when scores 
are ≥ 16. Participants’ attitudes towards DAART were also surveyed. Self-
efficacy, which measures one’s sense of control over his life circumstances, was 
assessed using the Self-Efficacy Form (24). Interviews were administered by non-
clinical research assistants in research settings, but also included hospitals, 
prisons and drug-treatment settings if necessary. Heavy drinking was defined as 
more than two drinks per day for men and more than 1 per day for women on 
average. Heavy cocaine use was defined as use for more than 5 days per month. 
The following baseline demographic and psychosocial characteristics were 
included in analysis: age, gender, race, homelessness, education, heavy drinking, 
any cocaine use, heavy cocaine use, injection drug use, drug abuse severity, CES-
D score, social support, self-efficacy, confidence that one can take medications as 
prescribed, preference for assistance with medication-taking, and willingness to 
travel for DAART. In addition, frequency of dosing, pill burden, and baseline 
viral load were included in analysis. 
All statistical analyses, including creation of persistence variables using 
the original dataset, were performed by Jason Bae and Eileen Ing using Stata SE 
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(version 10.1, Stata Corp, TX, USA). Crude odds ratios were calculated using 
bivariate logistic regression. Univariate variables with a P –value < 0.10 were 
included in the multivariate logistic regression modeling, which were used to 
calculate adjusted odds ratios. Firth’s penalized- likelihood logistic regression 
was used for bivariate analyses when complete separation occurred (25). Time to 
regimen non-persistence, stratified by the antiretroviral therapy based on the 1st 
day of DAART, was plotted as Kaplan–Meier curves, and a hazard ratio was 
calculated using Cox proportional-hazards regression. 
 
4. Results 
 
Definitions of Persistence in the setting of HIV Treatment 
 Adherence, the most frequent medication construct for HIV treatment, is 
defined as “the extent to which a patient’s behavior corresponds with the 
recommendations of a healthcare provider”, and is often synonymous with 
compliance (26).  In this thesis, we will use adherence to represent this construct.  
When adherence refers to taking medication, it generally quantifies the extent to 
which a patient acts in accordance with a prescribed interval and doses of a 
prescribed regimen within a given time period (27). By definition, it is expressed 
as a percentage of correctly timed doses (doses taken/doses prescribed x 100) 
(27).  Researchers and clinicians alike have tried to quantify the optimal level of 
adherence (e.g., greater than 95%) needed to simultaneously suppress viral 
replication and avoid development or resistance, yet these binary definitions 
have not been borne to be equally predictive for differing cART regimens (16). 
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Moreover, adherence thresholds have been plagued by measurement problems 
(e.g., self-report, electronic monitoring, pharmacy refills) and with quantifying 
exactly how much adherence is enough (16, 28). 
 Medication persistence, on the other hand, is also a medication-taking 
construct defined as “the duration of time from initiation to discontinuation of 
therapy (27).” By definition, it is expressed solely as a function of time, or the 
number of days (or months) on treatment. Alternatively, persistence can be 
expressed as a binary variable (persistent or non-persistent), measured at the end 
of a pre-specified time period. Similar to adherence, defining persistence as a 
binary variable is challenging due to the “permissible gap” in time that is 
allowed to pass after discontinuation of a prescribed regimen that is associated 
with a poor treatment outcome.  Permissible gaps, however, are likely to differ 
based on the type of cART regimen prescribed. 
 As with adherence, the concept of persistence may be applied to a variety 
of situations including taking medications, following dietary advice, and 
changing health habits.  Because persistence emphasizes the concept of 
continuous therapy, a permissible gap, the maximum number of consecutive 
doses that a patient can miss without expecting a reduced or suboptimal 
outcome, should be pre-specified in any assessment of persistence.  Such 
permissible gaps are ones that should have no negative clinical consequences for 
patients. 
 Medication persistence and adherence are similar in that they both 
measure the extent to which a patient’s behavior agrees with recommendations 
of a healthcare provider.  They differ, however, in the dimensions of this 
agreement. With regard to taking medications, adherence measures the 
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proportion of times that a patient takes medication as prescribed within a given 
interval, whereas persistence measures the duration of time that a patient 
continuously adheres to a prescribed regimen.  In other words, adherence 
measures “how often”, whereas persistence measures “for how long.” As such, 
these constructs are complimentary but distinct. 
 With regard to cART for the treatment of HIV, medication persistence 
merits further categorization, including: patient persistence and regimen persistence.  
Distinction between these constructs is described further.  
  
Patient Persistence 
 According to the stringent definition of persistence as a continuous 
therapy, a patient is persistent in adhering to the prescribed regimen as long as 
the permissible gap is not exceeded. A permissible gap can be defined as the 
maximum duration for which a patient may discontinue medication without 
experiencing a suboptimal outcome or adverse consequence. Due to the high 
replication capacity of HIV, the permissible gap for HIV treatment is likely to be 
on the magnitude of days rather than weeks (see below); however, since cART 
consists of multiple medications, often with different pharmacokinetic profiles, 
the permissible gap may vary depending on individual medications within a 
prescribed regimen. In addition, the duration of medication discontinuation 
necessary for development of a suboptimal outcome may also vary depending 
on the adverse consequence of interest (e.g. incomplete viral suppression, 
development of resistance, development of an adverse clinical event).  In the case 
of viral suppression, a permissible gap may be on the order of days while the 
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time to a clinical event (e.g., myocardial infarction or opportunistic infection) is 
likely to be on the order of months to years. 
 If a patient discontinues medication for a period that exceeds the 
permissible gap, the patient is no longer persistent with the HIV treatment. The 
duration of non-persistence is equivalent to the time lapsed between the first 
missed dose and re-initiation of therapy. A patient’s persistence with medication 
is expressed as a continuous variable in days (or weeks) with the goal being a 
lifetime.  
 
Regimen Persistence 
The concept of persistence may be extended beyond that of the individual 
patient and be applied to an entire antiretroviral regimen. This concept is most 
pertinent in resource-poor regions where available cART regimens are limited 
and unlike contemporary regimens in resource-rich settings, are less tolerable, 
have higher pill burdens and are pharmacologically inferior to newer regimens. 
We define regimen persistence as “the duration between the initiation and 
discontinuation of a specified antiretroviral regimen as agreed upon by the 
patient and the healthcare provider.” Using this definition, any change in any 
part of a regimen, for any reason, would result in the regimen being non-
persistent at the time of regimen discontinuation or modification.  
In contrast to patient persistence—a measure of a patient’s continued 
taking of cART, irrespective of the individual medications contained within the 
regimen—regimen persistence measures duration of a particular cART regimen 
as a means to suppress viral replication. Regimen persistence depends on factors 
both intrinsic and extrinsic to the regimen. Intrinsic factors include adverse side 
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effects, pill burden, underlying levels of resistance to one or more components of 
the regimen, and cost.  Extrinsic factors, those that contribute to a change in the 
components of the regimen, include new findings from clinical trials, new 
treatment guidelines, and availability of antiretroviral medications in a particular 
region. In contrast to patient persistence, the concept of a permissible gap is not 
applicable in the definition of regimen persistence; a regimen is persistent as long 
as it has not been explicitly modified or discontinued by either the patient or the 
healthcare provider.  
   
Patient Persistence, Regimen Persistence, and Adherence  
 While both are important, persistence and adherence are different but 
inter-related, as illustrated in Figure 2.  Adherence levels are indicated as a solid 
line, and HIV-1 RNA levels are shown as a dashed line. Optimal HIV viral 
suppression is observed when HIV-1 RNA levels fall below the dotted line. In 
this example, a patient initiates an NNRTI-based regimen and initially achieves 
virological suppression. Later, however, medications are discontinued 
completely (patient non-persistence or 0% adherence), resulting in virological 
rebound or replication to a detectable level. Alternatively, if the provider 
discontinued medications for any reason (low supply, too costly, etc), the patient 
would be persistent, the regimen would be non-persistent and the patient would 
be 100% adherent since the patient did what the clinician recommended.  Since 
the patient has discontinued medications for a period exceeding the permissible 
gap, he is no longer persistent with his original regimen; the patient is non-
persistent with medication for the duration between the first missed dose and the 
next dose of medication he takes (patient non-persistence in Figure 1). The 
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duration of patient persistence, in this case, is defined as the time period between 
the first dose and the last dose of the regimen [Patient (1) in Figure 1].  
 On the other hand, the regimen is persistent as long as it has not been 
explicitly modified or discontinued through agreement between the patient and 
the provider. Therefore, in this case, regimen persistence continues until the 
provider changes the NNRTI-based regimen to a boosted protease inhibitor (PI)-
based one [Regimen (1) in Figure 1]. Patient persistence is not affected by the 
regimen modification as long as the patient continuously adheres to medication 
without exceeding the permissible gap; the second phase of patient persistence 
[Patient (2) in Figure 1], which began with re-initiation of medication, continues 
despite the modification in regimen.  
 As demonstrated in this example, a regimen may be persistent while the 
patient is non-persistent. Likewise, a patient may be persistent with medication-
taking even when his regimen is changed as long as he continues to take his 
prescribed medications. Finally, a patient may be persistent while achieving a 
low level of adherence (sometimes defined as non-adherence). For example, if a 
patient is prescribed medication twice daily, but takes the regimen once daily 
everyday, he would be persistent but would maintain at a 50% adherence level. 
 
Methods for Determining Persistence 
 Measurement of persistence and methods to collect persistence data have 
been summarized previously (29, 30), and several methods may be used to 
determine persistence in HIV treatment (See Table 1). Patient persistence can be 
determined through measurements of a patient’s pill-taking history. These may 
include direct observation, Medication Event Monitoring System (MEMS), 
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patient self-report recall, review of pharmacy refill and medical records. Regimen 
persistence may also be determined using many of the same methods as in 
patient persistence plus a regimen change form on a study instrument in a 
prospective study. Reasons for patient or regimen non-persistence can be 
measured via a study instrument that assesses these constructs or by review of 
medical records. 
 Methods that yield high granularity of data, such as direct observation or 
MEMS, often require prospective studies and are likely to be expensive. 
Therefore, it is often impractical to gather this level of granularity in large 
retrospective studies. On the other hand, pharmacy refill records can be obtained 
with less cost and effort compared to other methods.  Pharmacy refill data, 
however, lack sufficient detail to adequately measure patient persistence, cannot 
accurately measure small permissible gaps in treatment, or answer why a 
regimen is no longer persistent, but are often satisfactory to measure regimen 
persistence per se.  
 
Impact of Persistence on Clinical Outcomes 
Patient Persistence 
 Patient non-persistence in HIV treatment has been insufficiently assessed 
in current research and is associated with adverse clinical outcomes. In a Spanish 
cohort study where the median duration of follow-up was 8.3 years, 43% of 
patients had a treatment interruption longer than 3 days, and these patients had 
a higher risk of treatment failure (31). In a Ugandan study with the median time 
on therapy was 38 weeks, 23% of patients had a history of treatment interruption 
greater than 4 days, which was significantly associated with virological failure 
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(32). Among injection drug users in Baltimore, 78% of subjects had one or more 
treatment discontinuations, and 20% of the study population never resumed 
cART (33).  
 In a study in which pill-taking history was measured using MEMS, 65% of 
patients had a treatment interruption longer than 48 hours in the 24 weeks 
observation period and were more likely to develop drug resistance than those 
without an interruption (34). Similarly, patients with a history of more than one 
drug holiday (patient non-persistence) lasting ≥ 48 hours were more likely to fail 
therapy and develop a resistance to NNRTI-containing regimens compared to 
those with one or less drug holiday (35). In another study, intermittent use of 
cART in the first year of therapy was significantly associated with increased 
mortality (36).  
 Results from prospective randomized controlled trials on structured 
treatment interruptions confirm that patient non-persistence adversely affects 
clinical outcomes in HIV-infected patients eligible for cART. In one trial, 
scheduled treatment interruptions exceeding 4 weeks were associated with 
development of resistance (37). In another study, a structured “1-week-on-1-
week-off” treatment strategy using cART was associated with increased 
likelihood of virological failure, and development of resistance among the 
patients taking an NNRTI-based regimen (15); these findings suggest that even 
missing one week of therapy has significant adverse consequences. In the 
randomized controlled SMART trial, planned cART discontinuation using a 
priori CD4 guidance thresholds was associated with increased rates of HIV- and 
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non-HIV-associated morbidity, decreased levels of HIV suppression, and lower 
CD4 counts, when compared to those who persisted with therapy (1). 
 On the other hand, in a randomized controlled treatment strategy of “five-
day-on, two-day-off” schedule of therapy in patients with durable virological 
suppression, 11 - 22% experienced virological failure among patients on a 
nevirapine- or PI-based regimen, however, no failure was observed among those 
on efavirenz-based regimens over 48 weeks of observation (14). Parienti and et 
al., using an observational analytical approach, demonstrated that frequent and 
longer duration of treatment interruption (non-persistence) were better 
predictors of virological rebound (i.e. failure) among patients on an NNRTI-
based regimen (38, 39). According to their logistic model, a treatment 
interruption of 15 days was associated with a 50% probability of virological 
rebound among those on an NNRTI-based regimen. On the other hand, higher 
average adherence rates overall appeared to be a better correlate of virological 
suppression among those on a boosted-PI-based regimen. These last two studies 
suggest that there may be unique properties of one or more of the components of 
the cART regimen that contributes to different permissible gaps in treatment 
interruptions that affect adverse clinical consequences 
 In sum, these data highlight that permissible gaps in HIV treatment may 
be as short as a few days and also vary depending on the unique 
pharmacokinetic and genetic barrier to resistance profiles of the various 
components of a cART regimen.  
 
Regimen Persistence 
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 Though reported measurements have been imperfect, persistence of an 
initial antiretroviral ranges from 11.8 months (40) to 34.3 months (41) with the 
trend toward longer persistence in more recent years. Though newer salvage 
regimens have resulted in markedly improved levels of viral suppression, it 
remains true that maintaining a patient on the initial regimen is likely to result in 
the greatest likelihood of virological suppression. Compared to the initial 
regimen, the second and the third regimens have significantly lower probability 
of achieving virological suppression (adjusted odds ratio 0.49 and 0.22, 
respectively, and p<0.02 for both) (41). Furthermore, each modification is 
associated with a more complex dosing schedule, a less favorable toxicity profile, 
and also decreased persistence of the subsequent regimen (41). In another study, 
patients who started on a persistent, NNRTI-based regimen were less likely to 
experience subsequent regimen modifications and a three-class regimen, 
compared to a less-persistent, PI-based regimen (42). 
  Regimen persistence is a particularly important issue in resource-poor 
settings, where available antiretroviral choices are limited and the medication 
alternatives are costly (39). Virological failure due to resistance to therapy may 
leave patients with few or no remaining treatment options.  
 
Factors that Affect Persistence  
 Adherence, patient persistence, and regimen persistence are intimately 
inter-related; they may be influenced by not only a similar set of patient, 
medication, and socioeconomic characteristics, but also by one another. For 
example, low adherence and frequent patient non-persistence due to toxicity of a 
regimen may lead to development resistance. Subsequent virological failure will 
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eventually result in modification of the patient’s regimen, leading to decreased 
regimen persistence. Existing literature on patient and medication characteristics 
that impact patient and regimen persistence is summarized below.  
 
Patient Characteristics 
 In the treatment of HIV infection, many patient characteristics contribute 
to decreased persistence. Clinical characteristics of patient-associated factors that 
have been associated with decreased patient persistence include female gender, 
high HIV RNA level, current substance use disorder (33), depression, and shorter 
time on cART (43). Younger age and black race have also correlated with 
decreased patient persistence (43).  
 Patient characteristics associated with regimen persistence are 
summarized in Table 2. These include: high or increasing HIV RNA levels (43-
47), low CD4 count prior to cART initation (46, 48), current high CD4 count (49, 
50), short duration on therapy (51), previous cART experience (40, 51) history of 
opportunistic infection (52), and hepatitis C virus co-infection (53) .  
 Also, affective mental disorders (41), depression (43, 47), use of alternative 
medicine, hospitalization (51), female gender (44, 50), men who have sex with 
men (50), black or minority race/ethnicity (38, 43, 54), younger age (43), low 
weight (48), lack of medical coverage (54, 55), and incarceration (56-58) have been 
associated with decreased regimen persistence.  
 Co-morbidities such as mental illness and substance use disorders are 
common among HIV-infected patients, and these patients frequently transition 
through correctional facilities (59, 60). Non-persistence is a great challenge in this 
population both within community and upon transition between a correctional 
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and a community setting. (57, 61, 62). In a study among HIV-infected prisoners, 
95% of released inmates failed to fill their cART prescription within 10 days of 
release (the time period for which medications were provided upon release), and 
patients therefore presumably did not take HIV medications beyond this period 
(61). Others have confirmed that HIV-1 RNA levels increase during this post-
release period; the finding that the HIV-1 RNA levels return to their pre-
treatment levels, and not just a partial increase, suggest that non-persistence 
rather than non-adherence is the mechanism of poor treatment outcomes (57). In 
another study of jail detainees, only 15% of those who were re-incarcerated 
repeatedly persisted with their medications.  Those who did not persist or who 
were never prescribed medications had increased likelihood of having higher 
HIV-1 RNA levels and decreasing CD4 counts (62). This suggests that patient 
non-persistence after release from prison or jail is common and is an important 
public health concern. 
 
Medication Characteristics  
 Existing data assessing the characteristics of a specific medication 
component or entire cART regimen on persistence primarily focus on regimen 
persistence. Medication characteristics associated with regimen persistence are 
summarized in Table 2. In Western countries, adverse events associated with 
cART and treatment failure were the two most common reasons for medication 
discontinuation or modification (44, 63). In addition, a greater number of 
medications within a regimen (45) and a more frequent dosing (41) were 
associated with early regimen discontinuation. In developing countries, in 
addition to adverse events and treatment failure, high cost and inadequate 
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supply of medications were cited as common reasons for regimen 
discontinuation among patients (51, 64). 
 Characteristics of individual antiretroviral medications within a cART 
regimen also influence regimen persistence. Overall, NNRTI-based regimens 
have been associated with increased persistence, compared to boosted or 
unboosted PI-based, triple-NRTI-based, or triple-class regimens (41, 65-67).  
Newer generations of NRTIs such as tenofovir, lamivudine, emtricitabine, and 
abacavir improve persistence compared to zidovudine, stavudine, and 
didanosine (41, 49, 50). Also, efavirenz has been associated with increased 
regimen persistence compared to nevirapine, and also the protease inhibitors 
lopinavir, saquinavir, and indinavir (33, 49, 64, 67). Among PIs, darunavir and 
atazanavir were less likely to result in regimen switch due to toxicity (50, 68), 
whereas lopinavir, saquinavir, and ritonavir were associated with 
discontinuation or modification of therapy (43, 44, 50). 
 In a recent trial in which patients were randomized to receive co-
formulated tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz or 
atazanavir boosted with ritonavir, lower rates of virological failure and increased 
persistence were observed among the group assigned to tenofovir/emtricitabine 
compared to abacavir/lamivudine (69).  Adverse consequence of abacavir 
resulted in medication discontinuation at a higher rate than for tenofovir.   
 
Healthcare Setting Characteristics 
 The organization of healthcare and even pharmacy services for patients 
impacts persistence.  For example, the frequency with which either clinicians 
choose to follow their patients or even how it is dictated by insurance or 
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managed healthcare providers can negatively influence persistence.  Prior 
authorization for medication changes has been associated with patient non-
persistence (70), as has co-pays and requirements for patients to spend down 
their personal resources before prescription benefits are renewed (71).  Most 
patients who become non-persistent do so without their provider actually 
knowing it until the patient’s next scheduled appointment (if the patient 
manages to return at all).  In the case of HIV-infected drug users, the onsite 
integration of buprenorphine treatment into HIV treatment settings resulted in 
improved retention in care and continuation of medications compared to those 
who were referred for treatment for their opioid dependence off-site (72).  Thus, 
organizational factors may contribute either to fragmented healthcare or less 
frequent monitoring, especially early in cART initiation, may disrupt continuity 
of cART and worsen HIV treatment outcomes.  
 
Persistence in Directly-Administered Antiretroviral Therapy among HIV-
infected drug users 
 Patient and regimen non-persistence defined and whose relevance to 
clinical and investigational considerations of HIV medication has been 
demonstrated above, were studied among HIV-infected injection drug users 
undergoing DAART in a randomized controlled setting. Results from this study 
are presented here. 
  
Patterns of Non-Persistence  
Of the 74 participants who initiated DAART in Project Trust, 15 (20%) 
were completely persistent, not missing 3 or more days, during the 6-month 
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intervention period. The patterns of non-persistence are described in Table 3. 
Among the 59 (80%) participants who were non-persistent for ≥ 3 days, the mean 
and median numbers of non-persistence episodes were 2.66 [standard error (SE): 
± 0.42] and 1.0 [interquartile range (IQR) 1–3], respectively. The mean and 
median lengths of non-persistence gaps were 15.0 (SE: ± 2.08) and 4.0 (IQR 3–6) 
days, respectively. Kaplan– Meier estimates for the time to first non-persistence 
gap, stratified by length of treatment lapses in therapy, are presented in Fig. 3. 
 
Factors Associated with Patient Non-Persistence  
Demographic, psychosocial, and medication characteristics along with 
other factors thought to be associated with patient non-persistence are presented 
in Table 4. Depression (CES-D≥16) was significantly associated with non-
persistence ≥ 3 days (AOR= 17.4; 95% CI: 1.5 – 204.1, p= 0.02).  Similarly, 
univariate analyses for non-persistence ≥ 7 days were significantly associated 
with having depression (OR=7.2; 95% CI: 1.5 – 35.7, p= 0.02) and having high 
addiction severity (OR=3.9; 95% CI: 1.5 – 10.2, p < 0.01).  The statistical 
significance for these outcomes was preserved in multivariable analysis for both 
depression (AOR=5.4; 95% CI: 1.1 – 27.5, p= 0.04) and high addiction severity 
(AOR=3.2; 95% CI: (1.1 – 9.2, p= 0.03).  No other factors were significantly 
associated with non-persistence ≥ 3 or ≥ 7 days.  Non-persistence ≥ 5 days was 
not significantly associated with any identified covariates. 
Of the 59 DAART participants who had any type of predefined non-
persistence, 31 (52.5%) had 2 or more episodes of non-persistence (Table 4). 
Univariate analyses showed statistically significant associations with injection 
drug use (OR=7.1; 95% CI: 1.4 – 36.9, p= 0.02), low self-efficacy (OR=0.3; 95%CI: 
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0.1 - 0.9, p= 0.03), and high-confidence in taking medications as prescribed 
(OR=0.3; 95% CI: 0.01 – 0.80, p=0.02). In multivariate analysis, and injection drug 
use (AOR=15.2; 95% CI:1.8 – 129.1, p= 0.02) was significantly associated with 
recurrent non-persistence. Twice daily dosing had a trend towards an increased 
risk of recurrent non-persistence compared to once daily dosing (AOR= 6.3, 95% 
CI:1.0 – 40.0, p= 0.05). 
 
Correlates of Virological Success 
In a univariate linear analysis, there was no statistically significant 
association between virological success and non-persistence (data not shown). 
 
Regimen Non-Persistence 
Among the 74 DAART participants, 20 (26%) modified their antiretroviral 
regimen during the 6-month intervention period and were thereby defined as 
having regimen non-persistence.  Of the demographic and psychosocial 
characteristics, only low social support (AOR=2.9; 95% CI: 1.0 – 8.4, p < 0.05) was 
statistically associated with regimen non-persistence. Time to regimen non-
persistence was significantly shorter for NNRTI-based regimen compared to a 
PI-based regimen (HR=3.0; 95% CI: 1.1 – 7.9; p= 0.03).  No significant relationship 
between regimen non-persistence and patient non-persistence was observed. 
 
5. Discussion 
 
Definition of medication persistence and review of literature 
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Much of research on HIV medication-taking behavior continues focus on 
adherence and mistakenly incorporates elements of persistence into its construct. 
Adherence and persistence are similar in that both constructs measure 
accordance of patient behavior with a prescribed therapy. In contrast to 
adherence, persistence is a longitudinal measure of antiretroviral therapy, with 
the emphasis on continuity rather than frequency.  
 In this thesis, we define medication persistence in the setting of HIV 
treatment and present patterns of non-persistence among HIV patients 
undergoing directly administered antiretroviral therapy.  We deconstruct 
persistence into two types: patient persistence and regimen persistence. The 
former measures continuous adherence to cART without exceeding a permissible 
gap, and the latter measures duration of a pre-specified cART regimen.  
 As cART regimens become more tolerable, less complex and are created 
with higher barriers to development of resistance, interventions designed to 
improve medication-taking behaviors need to increasingly focus on non-
persistence in addition to non-adherence.  Such interventions will likely need to 
incorporate measurement of persistence in real-time so that lapses in medication-
taking are averted promptly.  
 As summarized here, patient non-persistence is associated with adverse 
clinical outcomes, including higher rates of treatment failure, development of 
drug resistance, and increased mortality. Importantly, a longer duration and a 
higher frequency of patient non-persistence appear to increase the risk of adverse 
outcomes. 
 Patient non-persistence is of a major public health concern because viral 
resistance may develop during non-persistent periods and subsequently require 
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a more costly and toxic regimen for viral suppression. Furthermore, a higher 
viral load observed during non-persistent periods increases the risk of 
transmission of a potentially drug-resistant virus, if the patient engages in a risky 
behavior. 
 In addition to interventions that address patient characteristics associated 
with decreased persistence and clinical outcomes, such as substance abuse, 
incarceration, mental illness, and depression, new approaches may benefit both 
patients and the public. For example, a system in which failure of a patient to 
refill his or her medication in a scheduled time period leads to notification of his 
or her healthcare provider by the pharmacy would enable the physician to 
address the persistence issue with the patient and may prevent the patient from 
being non-persistent. Additionally, an improved coordination between a 
correctional and a community healthcare system would help many recently 
incarcerated HIV patients to remain persistent with therapy. Education of 
clinicians and patients of importance of continuous adherence, and impact of 
non-persistence and “drug holidays”, especially for NNRT-based regimens, may 
lead to a better decision-making with regards to selection and continuation of 
therapy. Adherence tools, such as schedules, dosettes, and electronic reminder 
systems, may also increase both adherence and persistence (73). Finally, in 
patients with a high risk of non-adherence and non-persistence may benefit from 
a directly observed therapy (20, 74, 75). 
 Each regimen change is associated with a diminished chance of viral 
suppression as well as higher toxicity and cost, and thus regimen persistence is 
an important issue from both clinical and public health perspectives. As 
summarized in this thesis, fewer drugs in a regimen, fixed-dose combinations, 
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newer generations of NRTIs, boosted-PIs, and efavirenz correlate with greater 
regimen persistence. Consideration of effects of each antiretroviral on regimen 
persistence is needed to maximize chances of prolonged viral suppression. 
 Limited availability of antiretroviral medications makes regimen 
persistence an especially important issue in resource-limited settings. 
Additionally, inconsistent supply of drugs may be a hindrance to patient as well 
as regimen persistence. Unfortunately, newer generations of antiretrovirals 
associated with increased persistence tend to be more costly and unavailable in 
developing countries.  
Last, the improved adherence with contemporary treatment regimens and 
data from the SMART trial remind clinicians and researchers that persistence, 
has become the “Achilles Heel” of HIV treatment and interventions that retain 
patients on effective treatment are urgently needed.   
 
Patterns of non-persistence in HIV-infected drug users receiving DAART in a 
randomized-controlled trial 
 We found a high rate of patient non-persistence among HIV-infection 
drug users receiving DAART. Among 74 subjects, 59 (80%) were non-persistent 
with therapy for 3 or more consecutive days, and 33 subjects (45%) for ≥7 
consecutive days. Thirty-one patients (42%) had more than one episode of non-
persistence lasting ≥3 days. These rates of medication non-persistence are higher 
than previously reported among diverse population within cohorts (31, 32, 34, 
35, 76).  
Several factors may be contributing to the high rate of non-persistence 
reported in this paper. First, our sample includes only active drug users and 
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drug users have been demonstrated to have problematic adherence to therapy 
(77, 78). This study also confirms that drug use, even in the setting of an 
evidence-based adherence intervention, is associated with problematic non-
persistence. Second, patient persistence data obtained through self-report in 
other studies may unrealistically underestimate the true frequency and length of 
non-persistent events, despite some studies suggesting adherence patterns can be 
accurately reported (79). 
In analysis of factors associated with non-persistence, high levels of 
addiction severity and depression were associated with an increased risk of non-
persistence. Additionally patients actively using injection drugs were more like 
to have multiple episodes of non-persistence. These results are consistent with 
other studies that have correlated active drug use and underlying psychiatric 
disorder with treatment interruptions, non-adherence, and poor HIV treatment 
outcomes (33, 77, 78, 80, 81) 
In this thesis, we did not find a significant association between patterns of 
patient non-persistence and virologic success, which is contrary to findings 
reported in previous studies reviewed here (31, 34, 35). Failure to find an 
association between non-persistence and virologic success in this study may be 
attributed to several factors.  
First, the small sample size likely resulted in an inadequate power avoid a 
Type II error. Second, both persistence and virologic outcome data were limited 
to 6 months of intervention, and it is possible that this period may have been 
insufficiently long enough to detect a statistically significant association, in 
contrast to other studies in which patients were followed for years. Third, the 
impact of non-persistence on virologic outcomes is likely different depending on 
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a patient’s antiretroviral regimen. Because of a low genetic barrier to resistance 
development as well as long half-lives of NNRTI’s, it is hypothesized that longer 
term non-persistence may have a greater negative impact on patients on an 
NNRTI-based regimen than those on a PI-based one; however, short treatment 
gaps may favor NNRTI-based regimens due to their longer half lives (38). A high 
proportion (60%) of patients on a PI-based regimen in this cohort may have 
required a greater power to detect a statistically significant association between 
non-persistence and virologic outcomes. 
 In analysis of factors associated with non-persistence, high levels of 
addiction severity were associated with an increased risk of non-persistence of 7 
days or more. Additionally, patients actively injecting drugs were more like to 
have multiple episodes of non-persistence. This study is the first to confirm the 
association of active drug use and severity on non-persistence in patients 
receiving DAART. 
Previous studies have reported that active drug users are at an increased 
risk of treatment interruptions (33), non-adherence (80) , and poor HIV treatment 
outcomes (77, 78). Our findings that patients with high levels of addiction 
severity and active use are at an increased risk of non-persistence and recurrent 
episodes of treatment gaps are consistent with existing literature, and therefore 
not surprising. Because of the grave impact active drug use has on adherence, 
persistence, and HIV outcomes, a substance dependence treatment program 
must be considered as an integral part of HIV treatment for active drug users. 
Buprenorphine/naloxone integrated into HIV treatment settings has shown 
promising results, and was associated with improved HIV treatment outcomes 
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among opioid-dependent patients infected with HIV, especially those treated for 
longer durations (82). 
HIV-infected patients with substance use disorders frequently have an 
underlying psychiatric disorder (60, 83). Since depression has been linked to 
decreased adherence and shorter survival as well as increased treatment 
interruptions (81), it is not surprising that patients with higher levels of 
depressive symptoms were less persistent with therapy. Incorporation of 
effective pharmacotherapy and counseling, as has been shown among homeless 
persons with HIV (84), in addition to treatment of active drug use, would benefit 
patients triply diagnosed with HIV, substance use, and depression. 
Finally, PI-based regimens were associated with increased regimen 
persistence compared to NNRTI-based regimens. This finding is also inconsistent 
with existing literature that NNRTI-based regimens tend to be more persistent 
than PI-based, triple-NRTI-based, or triple-class regimens (41, 65-67). One 
explanation for these results is that among drug users with high rates of non-
adherence and non-persistence, PI-based regimens may yield favorable 
treatment outcomes due to the shorter half-lives and higher genetic barrier to 
resistance development of PIs compared to NNRTIs; however, due to 
unavailability of data on reasons explaining regimen non-persistence (i.e. 
regimen modification), we cannot determine if this is in fact the case in this 
study. 
There are several important limitations to this study. The study 
population was small, restricted to a single inner-city community, and studied 
among those who received antiretroviral therapy via direct observation. This 
limits the generalizability of these findings. Furthermore, the analyses presented 
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here were not part of preplanned analyses comparing randomized groups. As 
such, the inferences made here must be considered as tentative and hypothesis-
generating rather than definitive. Patients who dropped out were considered 
non-persistent for the remaining duration of the study, although it is possible 
that they resumed or continued therapy in a non-research setting. Finally, pill-
pocketing or non-adherence to MEMS caps instructions, and associated bias in 
persistence data cannot be excluded. 
Further prospective studies are therefore needed to better understand 
both patient and regimen persistence, factors associated with them, and their 
impact on HIV treatment outcomes. 
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6. Figures 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic figure outlining the relationship between medication 
adherence and the risk of developing PI or NNRTI drug resistance. NNRTI-
treated individuals rarely develop resistance at high levels of adherence due to 
the virological effectiveness of these regimens. NNRTI resistance develops 
rapidly at moderate to low levels of resistance due to the low ‘fitness’ costs 
associated with single mutations. Single PI-treated individuals may develop 
resistance at high levels of adherence because residual viral replication is often 
seen in such patients. PI resistance is uncommon at low levels of adherence 
because of the significant fitness costs associated with these mutations. 
Resistance to a ritonavir- boosted PI is only possible in a narrow range of 
adherence where there is sufficient drug around to select for mutations that 
reduce ‘fitness’ while still allowing residual viral replication. Data in this figure 
are conceptual and based on trends observed in a number of recent studies (see 
text). PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase 
inhibitor. 
Reprinted from “Paradoxes of adherence and drug resistance to HIV 
antiretroviral therapy” by Bangsberg DR, Moss AR, Deeks SG. 2004 J Antimicrob 
Chemother 53: 696-699. 
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Figure 2. The relationship between patient persistence, regimen persistence, and 
adherence. Adherence levels are shown as a solid line and HIV-1 RNA levels as a 
dashed line. The dotted line represents optimal HIV viral suppression.   
PNP*= patient non-persistence  
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Figure 3. Time to patient non-persistence among DAART subjects, stratified by 
the length of non-persistence. A subject was categorized as “non-persistence ≥ 3 
days” if he missed 3 or more consecutive days of antiretroviral medications at 
any point during the DAART intervention period. Non-persistence ≥ 5 days and 
non-persistence ≥ 7 days were defined similarly. Each Kaplan-Meier failure curve 
represents the same population of subjects (N=74). 
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Figure 4. Time to regmien non-persistence among DAART subjects, stratified by 
the antiretroviral therapy backbone on the first day of DAART (N=74). Regimen 
non-persistence was defined as any change in antiretroviral medication during 
the intervention period of the study. The p-value was calculated with Cox 
proportional-hazards regression. (Legend:  NNRTI = non-nucleoside reverse 
transcriptate inhibitors; PI = protease inhibitor) 
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7. Tables 
 
Table 1:  Methods and Study Types to Measure Persistence 
 
 Prospective Retrospective 
Patient Persistence   
Directly Observed Therapy X  
MEMS cap X  
Patient recall X  
Pharmacy refill records X X 
Medical record review (e.g., notation 
of change or discontinuation) 
 X 
Reason for patient non-persistence 
(e.g., time gap) 
  
Questions on a study instrument X  
Review of medical records (e.g. 
adverse effects) 
 X 
Regimen Persistence   
Regimen change form on a study 
instrument 
X  
Patient recall X  
Pharmacy refill records X X 
Medical record review (e.g., notation 
of change or discontinuation) 
 X 
Reason for regimen non-persistence 
(e.g., regimen change) 
  
Questions on a study instrument X  
Review of medical records (e.g., viral 
load, adverse effects) 
 X 
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Table 2: Summary of Recent Studies on Regimen Persistence 
 
 
Study, Sample 
Size, Study 
Design, Time 
Period & Location 
Factors associated with 
decreased regimen persistence 
Factors associated with 
increased regimen 
persistence 
Reasons for 
regimen 
change or 
discontinuation 
Vo et al., 2008 (49) 
N=1866 
Sub-analysis study 
in a prospective 
cohort study 
2000-2005 
Switzerland 
ddI/another NRTI (ref: 
ZDV/3TC; aRRR: 2.06; 95% 
CI: 1.29-3.31) 
IDV/r (ref: EFV; aRRR: 2.28; 
95% CI: 1.24-4.17) 
HIV RNA >5 log10 copies/mL 
(aRRR: 1.35; 95% CI: 1.07-
1.71) 
CD4 count >350 cells/µl (ref: 
200-350 cells/µl; aRRR: 1.50; 
95% CI: 1.04-2.17) 
TDF/FTC or TDF/3TC 
(ref: ZDV/3TC; 
aRRR: 0.65; 95% CI: 
0.43-0.97) 
 
 
Reasons for 
regimen 
change 
included 
intolerance 
(51%), patient 
wish (15%), 
doctor decision 
(15%), and 
virological 
failure (7%).   
Lodwick et al., 
2008 (50) 
N=508 
Retrospective 
study of existing 
medical records 
2000-2005 UK 
d4T (ref: ZDV; IRR: 1.67; 
95%CI: 1.28–2.17)  
LVP (ref: EFV; IRR: 1.53; 95% 
CI: 1.21-1.94) 
SQV (ref: EFV; IRR: 1.75, 95% 
CI: 1.04–2.95) 
Higher CD4 count (for 100 
cells/µl increase; IRR: 1.06; 
95% CI: 1.02-1.11) 
ABC (ref: ZDV; IRR: 
0.29; 95% CI: 0.12-
0.67) 
TDF (ref: ZDV; IRR: 
0.61; 95% CI: 0.48-
0.79) 
Heterosexual men (ref: 
homosexual men or 
heterosexual 
women; p<0.05) 
Longer viral 
suppression (per 
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two-fold longer 
time; IRR: 0.90; 95% 
CI: 0.85-0.86) 
Willig et al., 2008 
(41) 
N=542 
Retrospective 
study of existing 
medical records 
2000-2007 USA 
 
Affective mental disorder 
(aHR: 1.43; 95% CI: 1.06-1.93) 
Twice-daily dosing (ref: once 
daily; aHR: 1.92; 95% CI: 
1.29-2.88) 
ddI or d4T (ref: ABC or TDF; 
aHR: 2.16; 95% CI: 1.09-4.26) 
Triple NRTI (ref: NNRTI; aHR: 
1.76; 95% CI: 1.14-2.73) 
Unboosted PI (ref: NNRTI; 
aHR: 1.58; 95% CI: 1.02-2.46) 
Boosted PI (ref: NNRTI; aHR: 
1.57; 95% CI: 1.02-2.41) 
  
Braithwaite et al., 
2007 (67) 
N=6394 
Retrospective 
study of existing 
medical records 
1996-2004 USA 
Single PI (ref: EFV, aHR: 1.16; 
p=0.003) 
Triple NRTI (ref: EFV, aHR: 
1.22; p=0.011) 
d4T/3TC (ref: ZDV/3TC, aHR: 
1.08 p=0.032)  
  
Li et al., 2005 (43) 
N=687 
Nested cohort 
study of a 
multicenter 
prospective cohort 
Younger age (per 5 year 
decrease; aOR: 1.20; 95% CI: 
1.03-1.40) 
High HIV RNA level (per 1 
log10 increase; aOR: 1.42; 95% 
CI: 1.17-1.72) 
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study 
1997-2001 USA 
Depression (aOR: 2.03; 95% CI: 
1.24-3.32) 
ABC (aOR: 1.82; 95% CI: 1.03-
3.20) 
LPV (aOR: 4.68; 95% CI: 1.56-
13.99) 
Pence et al., 2008 
(85) 
N=435 
Sub-analysis of a 
prospective cohort 
study 
2001-2002 USA 
Minority race/ethnicity (aHR: 
2.44; 95% CI: 1.33-4.49; 
p<0.05)  
 
  
Kiguba et al., 2007 
(51) 
N=686 
Cross-sectional 
study 
2005-2006 Uganda 
Previous cART experience 
(aOR: 3.70; 95% CI: 2.13-6.25) 
Use of alternative medicines 
(aOR: 2.18; 95% CI: 1.06-4.47) 
Hospitalization (aOR: 2.36; 
95% CI: 1.32-4.20) 
One year or less on cART 
(aOR: 11.11; 95% CI: 5.00-
25.00).  
Being unmarried (aOR: 1.64; 
95% CI: 1.02-2.70)  
3 months or less on cART 
(aOR: 3.13; 95% CI: 1.16-
8.33). 
 Reasons for 
discontinuation 
of cART 
included high 
cost (43.0%), 
adverse events 
(21.1%), drugs 
being out of 
stock (10.5%). 
Reasons for 
modification of 
cART were 
adverse events 
(71.8%) and 
high cost 
(23.3%). 
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Kumarasamy et 
al., 2006 (64) 
N=1443 
Retrospective 
study of existing 
medical records 
1996-2004 India 
NVP (ref: RTV or EFV), 
median 66 vs. 131 days; 
p=0.150).  
 Reasons for 
regimen 
modification 
included 
adverse events 
(64%) and cost 
(19%). 
Reasons for 
regimen 
discontinuation 
included cost 
(64%) and 
adverse events 
(21%). 
Willig et al., 2009 
(48) 
N=546 
Retrospective 
study of existing 
medical records 
2004-2007 Peru 
Weight < 60kg (aHR: 1.77; 95% 
CI: 1.25-2.51) 
Baseline CD4 <200 (aHR: 1.73; 
95% CI: 1.03-2.91) 
ZDV use at in the first 120 
days of therapy (aHR: 2.09; 
95% CI: 1.22-3.57) 
ZDV use >120 days 
after initiation of 
therapy (aHR: 0.52; 
95% CI: 0.28-0.95) 
 
Sax et al., 2009 
(69) 
N=1858 
Partially blinded 
randomized 
controlled trial 
2006-2009 USA 
ABC-3TC  (ref: TDF-FTC; HR: 
1.87; 95% CI (1.38-2.54); 
p<0.001) 
  
Domingo et al., LPV/r (ref: EFV, HR: 2.10, 95%   
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2008 (86) 
N=1550 
Sub-analysis of a 
prospective cohort 
study 
1999-2007 Spain 
Cl (1.40-3.15), p=0.0003) 
Springer et al., 
2007 (65) 
N=1099 
Retrospective 
cohort study 
1999-2002 USA  
Three class regimen (ref: Triple 
NRTI, NRTI-based, or PI-
base regimen; p<0.05) 
  
MacArthur el al., 
2006 (66) 
N=1397 
Randomized 
controlled trial 
1999-2002 USA 
Three class regimen (ref: 
NRTI-based or PI-base 
regimen; HR: 1.58; p<0.0001) 
 Most common 
adverse effects 
cited as a 
reason for 
discontinuation 
were nausea or 
vomiting, 
diarrhea, and 
rash. 
 
Abbreviations:  3TC, lamivudine; ABC, abacavir; aHR, adjusted hazard ratio; aOR, adjusted odds 
ratio; ATV, atazanavir; CI, confidence interval; d4T, stavudine; ddI, didanosine; EFV, efavirenz; 
FTC, emtricitabine; cART, combination antiretroviral therapy; HIV, human immunodeficiency 
virus; HR, hazard ratio; IDV/r, indinavir/ritonavir; IRR, incidence rate ratio; LPV, lopinavir; 
LPV/r, lopinavir/ritonavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NVP, nevirapine; OR, odds ratio; PI, protease inhibitor; 
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RNA, ribonucleic acid; aRRR, adjusted relative risk ratio; RTV, ritonavir; SQV, saquinavir; TDF, 
tenofovir; ZDV, zidovudine 
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Table 3. Patterns of patient non-persistence among subjects receiving directly 
administered antiretroviral therapy. 
  Non-persistence 
≥ 3 days  
Non-persistence 
≥ 5 days 
Non-persistence 
≥ 7 days 
All (n=74) 59 (80%) 41 (55%) 33 (45%) 
PI (n=44) 35 (80%) 23 (52%) 20 (45%) 
NNRTI (n=22) 17 (77%) 12 (55%) 7 (32%) 
Other (n=8) 7 (87.5%) 6 (75%) 6 (75%) 
Frequency of Dosing     
QD (n=21) 15 (71%) 10 (48%) 9 (43%) 
BID or more (n=53) 44 (83%) 31 (58%) 24 (45%) 
Pill Burden     
 <10 pills daily (n=40) 50 (83%) 35 (58%) 29 (48%) 
≥10 pills daily (n=34) 9 (64%) 6 (43%) 4 (29%) 
 
A subject was categorized as “non-persistence ≥ 3 days” if he missed 3 or more consecutive days 
of antiretroviral medications at any point during the DAART intervention period. Non-
persistence ≥ 5 days and non-persistence ≥ 7 days were defined similarly. 
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Table 4. Adjusted odds ratios of factors associated with patient non-
persistence among subjects receiving directly administered antiretroviral 
therapy. 
 Non-persistence ≥ 
3 days 
Non-persistence ≥ 
7 days 
Recurrent episodes 
of gaps (≥ 3 days) 
Homeless    
No (n=45) Referent    
Yes (n=29) 0.10 (0.01 – 1.01)   
Drug Abuse Severity (DAST-10)    
Low or moderate (n=38)  Referent  
High (n=36)  3.17 (1.1 – 9.14)*  
Injection drug use in past 30 days    
No   Referent 
Yes   15.20 (1.79 – 
129.11)* 
Depression (CES-D≥16)    
No (n=14) Referent Referent Referent 
Yes (n=55) 17.38 (1.48 – 
204.13)* 
5.41 (1.06 – 27.53)* 2.89 (.60 – 13.95) 
Preference for medication taking    
Prefers assistance (n=18) Referent   
Prefers no assistance (n=53) 0.30 (0.04 – 2.59)   
Baseline viral load    
VL<400 copies/mL (n=21) Referent   
VL≥400 copies/mL (n=53) 2.73 (0.67 – 11.23)   
Social Support    
High   Referent 
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Low   3.29 (.84 – 12.87) 
Self-Efficacy     
High   Referent 
Low   0.37 (.11 – 1.28) 
Frequency of dosing    
Once daily   Referent 
Twice daily   6.32 (1.00 – 39.98) 
Confidence can take medications 
as prescribed 
   
9 or 10 (Extremely confident)   Referent 
8 or lower   .40 (.10 – 1.60) 
 
Univariate analysis between the following variables in non-persistence ≥ 3, ≥ 5, and ≥ 7 days, and 
recurrent episodes of gaps ≥ 3 were performed. Age, gender, race, homelessness, education, drug 
abuse screening test, CES-D score, social support, self-efficacy, confidence that one can take 
medications as prescribed, preference for assistance with medication-taking, willingness to travel 
for DAART, frequency of dosing, pill burden, and baseline viral load. Those variables with a p-
value <0.10 on univariate analysis were included in the multivariate logistic regression and their 
adjusted odds ratios are presented here. Analyses for non-persistence ≥ 5 are not shown because 
no univariate association had a p –value <0.10. 
*p<0.05  
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